Apellis Pharmaceuticals Inc (APLS) support and resistance · rev $781.4M
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
This page maps Apellis Pharmaceuticals Inc (APLS) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
APLS currently screens at market cap $2.29B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new APLS 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the APLS quote page for the session range and the stock page for the full model.
Not investment advice.